investorscraft@gmail.com

Cidara Therapeutics, Inc. (CDTX)

Previous Close
$48.78
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)1520.003016
Intrinsic value (DCF)0.00-100
Graham-Dodd Methodn/a
Graham Formula2289.694594

Company Information

6310 Nancy Ridge Drive
San Diego, CA 92121
United States
Phone: 858 752 6170
Industry: Biotechnology
Sector: Healthcare
CEO: Dr. Jeffrey L. Stein Ph.D.
Full Time Employees: 38

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

HomeMenuAccount